Oncoclínicas offloads Spain's Medsir for €1 to end arbitration
What's the deal? OncoclínicasDealroom has a profile for this one. Try Dealroom → said on September 22 that its wholly owned subsidiary Idengene Medicina Diagnóstica has sold its entire stake in Spanish company MedsirDealroom has a profile for this one. Try Dealroom → to AAJ Capital 3 CorpDealroom has a profile for this one. Try Dealroom → for a symbolic €1. The transaction also ends an arbitration proceeding the buyer had started against the Brazilian oncology group.
Why now? The sale closes out future obligations tied to the investment — for both Idengene and Oncoclínicas — that could have reached up to €52 million.
What's the endgame? Oncoclínicas is shedding a foreign holding that carried significant potential liabilities, swapping a legal fight for a clean exit. The agreement also provides for partial repayment of a convertible loan worth €350,000, which will go towards buying medicines.
The signal: A €1 price tag underlines how far the deal is about cutting risk rather than realising value. For Oncoclínicas, walking away from Medsir removes a contingent exposure many times the size of anything the asset could return.
Read more: valor.globo.com
Image credit: Generated with Gemini
